tissue solutions limited

Live EstablishedSmallHigh

tissue solutions limited Company Information

Share TISSUE SOLUTIONS LIMITED

Company Number

SC331666

Directors

Miguel Tobin

Piyush Shukla

View All

Shareholders

the intelligent tissue group limited

Group Structure

View All

Industry

Other human health activities

 

Registered Address

cypex ltd 6 tom mcdonald avenue, dundee, DD2 1NH

tissue solutions limited Estimated Valuation

£2.4m

Pomanda estimates the enterprise value of TISSUE SOLUTIONS LIMITED at £2.4m based on a Turnover of £3.9m and 0.61x industry multiple (adjusted for size and gross margin).

tissue solutions limited Estimated Valuation

£4.2m

Pomanda estimates the enterprise value of TISSUE SOLUTIONS LIMITED at £4.2m based on an EBITDA of £908.8k and a 4.67x industry multiple (adjusted for size and gross margin).

tissue solutions limited Estimated Valuation

£222.1m

Pomanda estimates the enterprise value of TISSUE SOLUTIONS LIMITED at £222.1m based on Net Assets of £89.1m and 2.49x industry multiple (adjusted for liquidity).

Edit your figures and get a professional valuation report.

Tissue Solutions Limited Overview

Tissue Solutions Limited is a live company located in dundee, DD2 1NH with a Companies House number of SC331666. It operates in the other human health activities sector, SIC Code 86900. Founded in October 2007, it's largest shareholder is the intelligent tissue group limited with a 100% stake. Tissue Solutions Limited is a established, small sized company, Pomanda has estimated its turnover at £3.9m with high growth in recent years.

View Sample
View Sample
View Sample

Upgrade for unlimited company reports & a free credit check

Tissue Solutions Limited Health Check

Pomanda's financial health check has awarded Tissue Solutions Limited a 5 rating. We use a traffic light system to show it exceeds the industry average on 6 measures and has 1 areas for improvement. Company Health Check FAQs

Health Check Image
Health Rating5out of 5
positive_score

6 Strong

positive_score

4 Regular

positive_score

1 Weak

size

Size

annual sales of £3.9m, make it larger than the average company (£820k)

£3.9m - Tissue Solutions Limited

£820k - Industry AVG

growth

Growth

3 year (CAGR) sales growth of 17%, show it is growing at a faster rate (4.7%)

17% - Tissue Solutions Limited

4.7% - Industry AVG

production

Production

with a gross margin of 39.2%, this company has a comparable cost of product (36.4%)

39.2% - Tissue Solutions Limited

36.4% - Industry AVG

profitability

Profitability

an operating margin of 22.8% make it more profitable than the average company (7%)

22.8% - Tissue Solutions Limited

7% - Industry AVG

employees

Employees

with 16 employees, this is similar to the industry average (19)

16 - Tissue Solutions Limited

19 - Industry AVG

paystructure

Pay Structure

on an average salary of £25.5k, the company has an equivalent pay structure (£25.5k)

£25.5k - Tissue Solutions Limited

£25.5k - Industry AVG

efficiency

Efficiency

resulting in sales per employee of £246k, this is more efficient (£49.6k)

£246k - Tissue Solutions Limited

£49.6k - Industry AVG

debtordays

Debtor Days

it gets paid by customers after 22 days, this is near the average (23 days)

22 days - Tissue Solutions Limited

23 days - Industry AVG

creditordays

Creditor Days

its suppliers are paid after 75 days, this is slower than average (17 days)

75 days - Tissue Solutions Limited

17 days - Industry AVG

stockdays

Stock Days

There is insufficient data available for this Key Performance Indicator!

- - Tissue Solutions Limited

- - Industry AVG

cashbalance

Cash Balance

has cash to cover current liabilities for 4 weeks, this is less cash available to meet short term requirements (106 weeks)

4 weeks - Tissue Solutions Limited

106 weeks - Industry AVG

debtlevel

Debt Level

it has a ratio of liabilities to total assets of 5.4%, this is a lower level of debt than the average (27.5%)

5.4% - Tissue Solutions Limited

27.5% - Industry AVG

TISSUE SOLUTIONS LIMITED financials

EXPORTms excel logo

Tissue Solutions Limited's latest turnover from December 2022 is £3.9 million and the company has net assets of £89.1 million. According to their latest financial statements, Tissue Solutions Limited has 16 employees and maintains cash reserves of £467.1 thousand as reported in the balance sheet.

Data source: Companies HousePomanda Estimates

Dec 2022Dec 2021Apr 2021Sep 2020Sep 2019Sep 2018Sep 2017Sep 2016Sep 2015Sep 2014Sep 2013Sep 2012Sep 2011Sep 2010Sep 2009
Turnover3,936,5412,069,0403,362,8002,800,6092,488,4222,872,4512,025,6651,929,8972,252,7822,994,8692,553,4801,647,489579,400818,2860
Other Income Or Grants000000000000000
Cost Of Sales2,393,5241,674,9932,686,3532,200,7611,954,3112,245,2451,533,6561,469,9551,753,3372,279,7491,940,0741,198,147414,323584,6490
Gross Profit1,543,017394,047676,446599,848534,111627,206492,008459,942499,446715,120613,406449,342165,077233,6370
Admin Expenses645,237-1,275,913-33,021-140,7682,711,241-249,253-990,066-136,387230,529492,909419,701254,016142,905209,228-67,125
Operating Profit897,7801,669,960709,467740,616-2,177,130876,4591,482,074596,329268,917222,211193,705195,32622,17224,40967,125
Interest Payable000000000000000
Interest Receivable02,6531,7811,15911,04514,2702,8679441,4892,0151,35878954027870
Pre-Tax Profit897,7801,672,614711,248741,775-2,166,085890,7281,484,941597,274270,406224,227195,064196,11422,71224,68867,196
Tax1,530-317,797-135,137-140,9370-169,238-282,139-119,455-54,081-47,088-44,865-47,067-5,905-6,912-18,815
Profit After Tax899,3101,354,817576,111600,838-2,166,085721,4901,202,802477,819216,325177,139150,199149,04716,80717,77548,381
Dividends Paid000000000000000
Retained Profit899,3101,354,817576,111600,838-2,166,085721,4901,202,802477,819216,325177,139150,199149,04716,80717,77548,381
Employee Costs408,320341,934328,546321,059473,852302,625278,116204,268657,185902,187834,867506,029187,762264,7190
Number Of Employees1614141421141310314239249130
EBITDA*908,8041,674,844713,945750,775-2,167,655885,0721,486,041602,062274,766228,556198,431198,07125,54227,26368,829

* Earnings Before Interest, Tax, Depreciation and Amortisation

Dec 2022Dec 2021Apr 2021Sep 2020Sep 2019Sep 2018Sep 2017Sep 2016Sep 2015Sep 2014Sep 2013Sep 2012Sep 2011Sep 2010Sep 2009
Tangible Assets19,55918,7754,77610,84817,16938,20316,79912,0597,37013,21914,5799,2642,9834,0053,520
Intangible Assets16,55516,58716,50016,91618,5830000000000
Investments & Other52,311,947008600000000000
Debtors (Due After 1 year)00000000565,730000000
Total Fixed Assets52,348,06135,36221,27627,85035,75238,20316,79912,059573,10013,21914,5799,2642,9834,0053,520
Stock & work in progress000113,56295,99556,77562,60950,8650000000
Trade Debtors246,878660,1091,020,481812,298781,499918,932672,336647,425347,196440,957344,571228,14071,571124,17687,615
Group Debtors7,534,3942,075,918300,55630,79001,211,782849,572650,0400000000
Misc Debtors33,608,993378,123244,100332,302151,06393,66028,36416,8190000000
Cash467,110632,6222,071,9011,489,970828,1712,117,0761,688,222605,351150,131445,392360,789182,536132,96083,03228,171
misc current assets000000000000000
total current assets41,857,3753,746,7723,637,0382,778,9221,856,7284,398,2253,301,1031,970,500497,327886,349705,360410,676204,531207,208115,786
total assets94,205,4363,782,1343,658,3142,806,7721,892,4804,436,4283,317,9021,982,5591,070,427899,568719,939419,940207,514211,213119,306
Bank overdraft000000000000000
Bank loan000000000000000
Trade Creditors 495,426384,032684,206673,057457,904692,924390,132321,521293,278337,574334,812186,075123,952144,25470,234
Group/Directors Accounts4,347,7609,368237,718121,0108,1940000000000
other short term finances000000000000000
hp & lease commitments000000000000000
other current liabilities270,840419,220546,896395,149409,066560,331468,450405,3730000000
total current liabilities5,114,026812,6201,468,8201,189,216875,1641,253,255858,582726,894293,278337,574334,812186,075123,952144,25470,234
loans000000000000000
hp & lease commitments000000000000000
Accruals and Deferred Income000000000000000
other liabilities000000000000000
provisions3,0172,1588445,0175,6155,3873,0242,1711,4742,6442,9161,853597801689
total long term liabilities3,0172,1588445,0175,6155,3873,0242,1711,4742,6442,9161,853597801689
total liabilities5,117,043814,7781,469,6641,194,233880,7791,258,642861,606729,065294,752340,218337,728187,928124,549145,05570,923
net assets89,088,3932,967,3562,188,6501,612,5391,011,7013,177,7862,456,2961,253,494775,675559,350382,211232,01282,96566,15848,383
total shareholders funds89,088,3932,967,3562,188,6501,612,5391,011,7013,177,7862,456,2961,253,494775,675559,350382,211232,01282,96566,15848,383
Dec 2022Dec 2021Apr 2021Sep 2020Sep 2019Sep 2018Sep 2017Sep 2016Sep 2015Sep 2014Sep 2013Sep 2012Sep 2011Sep 2010Sep 2009
Operating Activities
Operating Profit897,7801,669,960709,467740,616-2,177,130876,4591,482,074596,329268,917222,211193,705195,32622,17224,40967,125
Depreciation10,9924,8764,06210,1599,4758,6133,9675,7335,8496,3454,7262,7453,3702,8541,704
Amortisation328416000000000000
Tax1,530-317,797-135,137-140,9370-169,238-282,139-119,455-54,081-47,088-44,865-47,067-5,905-6,912-18,815
Stock0-113,562-113,56217,56739,220-5,83411,74450,8650000000
Debtors38,276,1151,938,760389,747242,828-1,291,812674,102235,988401,358471,96996,386116,431156,569-52,60536,56187,615
Creditors111,394-289,02511,149215,153-235,020302,79268,61128,243-44,2962,762148,73762,123-20,30274,02070,234
Accruals and Deferred Income-148,38024,071151,747-13,917-151,26591,88163,077405,3730000000
Deferred Taxes & Provisions859-2,859-4,173-5982282,363853697-1,170-2721,0631,256-204112689
Cash flow from operations-37,401,908-735,964461,346550,081-1,301,120444,6021,088,711464,697-296,75087,572186,93557,81451,73657,92233,322
Investing Activities
capital expenditure-11,776-12,4822,010-2,171-7,024-30,017-8,707-10,4220-4,985-10,041-9,026-2,348-3,339-5,224
Change in Investments52,311,947-86-868600000000000
cash flow from investments-52,323,723-12,3962,096-2,257-7,024-30,017-8,707-10,4220-4,985-10,041-9,026-2,348-3,339-5,224
Financing Activities
Bank loans000000000000000
Group/Directors Accounts4,338,392-111,642116,708112,8168,1940000000000
Other Short Term Loans 000000000000000
Long term loans000000000000000
Hire Purchase and Lease Commitments000000000000000
other long term liabilities000000000000000
share issue85,221,72700000000000002
interest02,6531,7811,15911,04514,2702,8679441,4892,0151,35878954027870
cash flow from financing89,560,119-108,989118,489113,97519,23914,2702,8679441,4892,0151,35878954027872
cash and cash equivalents
cash-165,512-857,348581,931661,799-1,288,905428,8541,082,871455,220-295,26184,603178,25349,57649,92854,86128,171
overdraft000000000000000
change in cash-165,512-857,348581,931661,799-1,288,905428,8541,082,871455,220-295,26184,603178,25349,57649,92854,86128,171

tissue solutions limited Credit Report and Business Information

Very Low Risk70 - 100
Low Risk50 - 70
Moderate Risk30 - 50
High Risk20 - 30
Very High Risk0 - 20
Get a comprehensive credit check for tissue solutions limited. Get real-time insights into tissue solutions limited's credit score, group structure and payment trends.

From as little as £6.99

This will not impact your credit rating!

View Credit Report Sample

Tissue Solutions Limited Competitor Analysis

competitor_analysis_table_img

Perform a competitor analysis for tissue solutions limited by selecting its closest rivals, whether from the HUMAN HEALTH AND SOCIAL WORK ACTIVITIES sector, other small companies, companies in DD2 area or any other competitors across 12 key performance metrics.

tissue solutions limited Ownership

TISSUE SOLUTIONS LIMITED group structure

Tissue Solutions Limited has no subsidiary companies.

Ultimate parent company

BIOIVT LLC

#0169546

2 parents

TISSUE SOLUTIONS LIMITED

SC331666

TISSUE SOLUTIONS LIMITED Shareholders

the intelligent tissue group limited 100%

tissue solutions limited directors

Tissue Solutions Limited currently has 8 directors. The longest serving directors include Mr Miguel Tobin (Apr 2021) and Mr Piyush Shukla (Oct 2021).

officercountryagestartendrole
Mr Miguel TobinScotland39 years Apr 2021- Director
Mr Piyush ShuklaScotland48 years Oct 2021- Director
Mr Piyush ShuklaEngland48 years Oct 2021- Director
Mr Adam FriedmanScotland34 years Oct 2021- Director
Mr Adam FriedmanScotland34 years Oct 2021- Director
Mr Richard HaighScotland56 years Sep 2022- Director
Mr Andrea RomoliUnited States51 years Jun 2023- Director
Ms Laurie FullerUnited Kingdom58 years Jun 2023- Director

P&L

December 2022

turnover

3.9m

0%

operating profit

897.8k

0%

gross margin

39.2%

0%

turnover

Turnover, or revenue, is the amount of sales generated by a company within the financial year.

Balance Sheet

December 2022

net assets

89.1m

+29.02%

total assets

94.2m

+23.91%

cash

467.1k

-0.26%

net assets

Total assets minus all liabilities

tissue solutions limited company details

company number

SC331666

Type

Private limited with Share Capital

industry

86900 - Other human health activities

incorporation date

October 2007

age

18

incorporated

UK

ultimate parent company

BIOIVT LLC

accounts

Audit Exemption Subsidiary

last accounts submitted

December 2022

previous names

N/A

accountant

MAZARS LLP

auditor

-

address

cypex ltd 6 tom mcdonald avenue, dundee, DD2 1NH

Bank

HSBC BANK PLC

Legal Advisor

-

tissue solutions limited Charges & Mortgages

A charge, or mortgage, refers to the rights a company gives to a lender in return for a loan, often in the form of security given over business assets.

We did not find charges/mortgages relating to tissue solutions limited.

tissue solutions limited Capital Raised & Share Issues BETA

When a company issues new shares, e.g. to new investors following a funding round, it is required to notify Companies House within one month of making an allotment of shares.

Click to start generating capital raising & share issue transactions for TISSUE SOLUTIONS LIMITED. This can take several minutes, an email will notify you when this has completed.

tissue solutions limited Companies House Filings - See Documents

datedescriptionview/download